The addition of a tumor necrosis factor inhibitor to steroid therapy reduced acute stage disease duration and hospital stay in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis, according to a study.
“Systemic steroid therapies for Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) have been challenged due to their limited benefits,” Suiting Ao, MD, of the department of dermatology at The First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, and colleagues wrote. “Whether additional tumor necrosis factor (TNF)-alpha inhibition